SOURCE: Novartis International

May 21, 2007 18:13 ET

Novartis Pursues Legal Actions to Defend Intellectual Property Rights for High Blood Pressure Medicine Lotrel Following US Court Ruling

BASEL, SWITZERLAND -- (MARKET WIRE) -- May 21, 2007 --

--  Novartis has a valid US patent for Lotrel -- a single-tablet
    combination therapy for high blood pressure -- until December 2017, will
    continue to enforce patent rights
--  US judge extends temporary restraining order until May 29 but allows
    Teva to sell any Lotrel generics already shipped to distributors and
--  Novartis evaluating potential impact of Teva actions on full-year 2007
Novartis is pursuing its legal defense after a US federal court judge on Monday extended a temporary restraining order related to a patent infringement lawsuit involving Lotrel® until May 29 and stopped Teva Pharmaceuticals from shipping any further generic copies of this Novartis medicine to distributors and customers until further notice.

However, the judge has allowed Teva to sell any generic copies of Lotrel, a single-tablet combination therapy for patients with high blood pressure, that reached distributors and customers before a court order on Saturday to halt sales before Monday's hearing.

US District Court Judge Dennis M. Cavanaugh issued the ruling on Monday after the issuance of the temporary restraining order on May 19, a day after Teva received final US Food and Drug Administration (FDA) approval for its generic version and began shipments to customers.

Novartis sought the restraining order since it still has a valid US patent for Lotrel that does not expire until December 2017. The US approval does not mitigate Teva's patent infringement in launching a generic version. Novartis will continue to vigorously defend its intellectual property rights, including the validity of the Lotrel patent, against any generic challengers.

Also on Monday, the judge prevented Novartis from launching a so-called "authorized generic" version of Lotrel, which is sold only in the US, until the next hearing in this lawsuit on May 29. A hearing on a preliminary injunction sought by Novartis to prevent the launch of Teva's generic version of Lotrel currently remains scheduled for July 11.

Novartis filed a patent infringement lawsuit in a US district court in New Jersey against Teva in September 2004 after Teva sought approval from the US Food and Drug Administration to market a generic version of Lotrel. The patent for Lotrel (No. 6162802) covers, among other aspects, a pharmaceutical composition of amlodipine besylate and benazepril hydrochloride. Both of these active ingredients no longer have patent protection in the US.

Lotrel is a leading high blood pressure medicine sold only in the US that combines in a single tablet the angiotensin converting enzyme (ACE) inhibitor benazepril hydrochloride and the calcium channel blocker (CCB) amlodipine besylate.

Financial update

Novartis is evaluating the potential impact of Teva's actions on the full-year 2007 net sales, operating and net income results. Lotrel, which is sold only in the US, had 2006 annual sales of USD 1.35 billion.


The foregoing release contains forward-looking statements which can be identified by the use of terminology such as "pursuing," "will continue," "evaluating," "potential," "scheduled" or similar expressions, or by express or implied discussions regarding the patent life of Lotrel, the potential for the continued maintenance of the injunction imposed against Teva, the potential for Novartis to succeed in the underlying litigation against Teva, potential future revenue to be earned from Lotrel and the potential impact of Teva's actions on the net sales, operating income and net income results for Novartis. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Novartis will be successful in its efforts to defend its Lotrel patent, or that the court will continue to impose an injunction against the marketing of a generic version of Lotrel by Teva, or that Novartis will ultimately succeed in its litigation against Teva. Neither can there be any guarantees that Lotrel will achieve or maintain any particular sales levels in the future or that the Novartis Group will achieve any particular levels of net sales, operating income or net income results. In particular, management's expectations regarding Lotrel could be affected by, among other things, uncertainties involved in US patent law and the US litigation process; the company's ability to maintain patent or other proprietary intellectual property protection; increased government, industry, and general public pricing pressures; competition in general; unexpected regulatory actions or delays or government regulation generally; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit

Media release (PDF)

Contact Information

  • Novartis Media Relations

    John Gilardi
    Novartis Global Media Relations
    +41 61 324 3018 (direct)
    +41 79 596 1408 (mobile)
    Email Contact

    Sherry Pudloski
    Novartis Pharmaceuticals Corporation
    +1 862 778 1271 (direct)
    +1 917 620 4446 (mobile)
    Email Contact

    e-mail: Email Contact

    Novartis Investor Relations

    Ruth Metzler-Arnold
    +41 61 324 7944

    Katharina Ambühl
    +41 61 324 5316

    Nafida Bendali
    +41 61 324 3514

    Jason Hannon
    +41 61 324 2152

    Thomas Hungerbuehler
    +41 61 324 8425

    Richard Jarvis
    +41 61 324 4353

    North America:
    Ronen Tamir
    +1 212 830 2433

    Arun Nadiga
    +1 212 830 2444

    Jill Pozarek
    +1 212 830 2445

    Edwin Valeriano
    +1 212 830 2456

    e-mail: Email Contact